Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Core Viewpoint - Greenwich LifeSciences, Inc. has extended the lock-up period for shares owned by its directors, officers, and pre-IPO investors to March 31, 2026, which is approximately 66 months post-IPO, restricting their ability to sell shares during this time [1] Group 1: Company Overview - Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on developing GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences in patients who have undergone surgery [4] - The company is currently conducting a Phase III clinical trial named FLAMINGO-01, which evaluates the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients [2] Group 2: Clinical Trial Details - FLAMINGO-01 is designed to include approximately 500 HLA-A*02 patients randomized to receive either GLSI-100 or a placebo, with an additional arm for up to 250 patients of other HLA types receiving GLSI-100 [2] - The trial aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, requiring 28 events for analysis, with an interim analysis planned after 14 events [2] Group 3: Market Context - In the U.S., one in eight women will develop invasive breast cancer, with around 300,000 new cases and 4 million survivors annually [3] - HER2 protein is expressed in approximately 75% of breast cancers, highlighting the potential market for therapies targeting this receptor [3]